By Fineline Cube 
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.
Product Revenue Growth
The increase in product revenue was primarily driven by stronger sales of Brukinsa. The U.S. remained the largest market for BeiGene, generating product revenue of USD 563 million in Q1 2025, compared to USD 351 million in the same period last year. In-licensed products from Amgen and Tevimb also contributed to the growth in product revenue. U.S. sales of Brukinsa alone reached USD 563 million in Q1 2025, a 60% increase from the prior-year period, primarily due to increased demand. More than 60% of the quarter-over-quarter growth stemmed from expanded use in chronic lymphocytic leukemia (CLL), with Brukinsa continuing to lead in new patient starts in the U.S. across CLL and all other approved indications. Brukinsa sales in Europe totaled USD 116 million in Q1 2025, a 73% increase from the prior-year period, driven by increased market share across major European markets, including Germany, Italy, Spain, France, and the UK. Sales of Tevimbra reached USD 171 million in Q1 2025, an 18% increase from the prior-year period.
Financial Guidance
BeiGene projects total revenue of USD 4.9–5.3 billion for the year, reflecting strong growth expectations for Brukinsa’s U.S. market dominance and continued global expansion.-Fineline Info & Tech